Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 5/20 | 0.49 |
| ▸ | LCK | P06239 | 6/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27581640 | 1.00 | JAK2 (0.52) | JAK2JAK3IDH1LCKGPR55 | |
| SCHEMBL27581646 | 0.92 | LCK (0.53) | JAK2JAK3IDH1LCKMAPK13 | |
| SCHEMBL6981895 | 0.92 | LCK (0.53) | JAK2JAK3IDH1LCKMAPK13 | |
| SCHEMBL27560843 | 0.90 | LCK (0.57) | JAK2JAK3IDH1LCKMAPK13 | |
| SCHEMBL6985098 | 0.90 | LCK (0.57) | JAK2JAK3IDH1LCKMAPK13 | |
| SCHEMBL27581600 | 0.87 | LCK (0.52) | JAK2JAK3IDH1LCKMAPK13 | |
| SCHEMBL6986643 | 0.87 | LCK (0.52) | JAK2JAK3IDH1LCKMAPK13 | |
| SCHEMBL6986826 | 0.86 | LCK (0.48) | JAK2JAK3IDH1LCKMAPK13 | |
| SCHEMBL28749777 | 0.86 | LCK (0.48) | JAK2JAK3IDH1LCKMAPK13 | |
| SCHEMBL6987170 | 0.85 | ADRA1D (0.51) | IDH1LCKMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224180-B1 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2003-07-02 | — | — | EP | claimed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | claimed |
| CN-1378544-A | Substituted azoles compounds | NOVARTIS AG (CH) | 2002-11-06 | — | — | CN | claimed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | claimed |
| EP-1224180-B1 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | disclosed |
| CN-1378544-A | Substituted azoles compounds | NOVARTIS AG (CH) | 2002-11-06 | — | — | CN | disclosed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049220-A1 | Substituted azoles | MAPK1, MAPK4, MAP3K1 | JAK2 179/4885JAK3 440/4885IDH1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.